Resources

Brainomix, a global leader and pioneer of AI-powered imaging biomarkers for stroke and lung fibrosis, has announced results from its partnership with Argenica Therapeutics for imaging and clinical data analysis of the Phase II trial evaluating ARG-007, a neuroprotective agent for acute ischemic stroke.

Our final blog of 2025 celebrates some excellent fundraising news to close the year, while highlighting key opportunities to engage with and shape the UK life sciences agenda — including the development of UK engineering biology, data policy, a cross-cancer research policy position and salary benchmarking.

Scancell Holdings, the developer of active immunotherapies to treat cancer, announces updated positive data from the SCOPE Phase 2 trial of iSCIB1+ in combination with ipilimumab and nivolumab, current standard of care (SoC).

Brainomix has published a prospective real-world study demonstrating that its AI imaging platform, Brainomix 360 Stroke, significantly increased rates of endovascular thrombectomy (EVT) treatment.

From stronger STEM foundations and digital/AI literacy in schools to clearer post-16 technical pathways and lifelong learning opportunities, these reforms offer a once-in-a-generation chance to prepare a workforce ready for the next wave of biotech innovation.

Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in macrophage mediated antifibrotic therapy.

In this blog, Dr Kate Barclay, Skills Strategy Consultant at BIA, explores two pivotal developments — the National Curriculum review and Skills England’s AI Skills for the UK Workforce report — and what they mean for preparing the next generation of scientifically confident, AI-literate talent for biotech.

In a landscape where efficiency, scalability, and quality are critical, automation is no longer just about doing more; it’s about understanding more. Olivia Dell-Price, Pharmaceutical Automation Specialist at Labman, explores how the future of biomanufacturing is becoming intelligent, connected and data-driven.

AI-powered protein engineering promises speed, precision and scalability - but only if you have the right data. For most teams, that’s the biggest barrier. For ACROBiosystems, it’s a decade-long advantage. Read this blog by Ruiyuan Zheng, Marketing Product Manager, ACROBiosystems, to learn more about how they solved it. 

Brainomix earned top recognition in the Science category for its innovative approach to improving outcomes for patients affected by cardiovascular disease and stroke.

The UK biotech financing numbers for Q3 are out, showing validation of UK assets but a sector under strain from prolonged global headwinds. Time to double down on investment in innovation as a driver for growth and deploy Industrial Strategy plans with urgency.

​​​​​​​Following a landmark TechBio Week, we reflect with some insights from our flagship conference on the transformative potential for growth of technological advances in the sector.

Results from a US multicenter study presented at CHEST show e-Lung could have sped up Progressive Pulmonary Fibrosis (PPF) diagnosis by up to 21 months

Major 2025 deals from Isomorphic Labs and CHARM Therapeutics validate the sector's maturity as it calls for domestic capital to close the 'scale-up gap.' 

It’s TechBio week and we’re celebrating the UK’s leading role in AI and life sciences with significant investment and interest from global players and our own flagship TechBio UK conference and 2025 report launch. 

Good to see support for BIA agendas in government messaging as we continue to push for pension fund reform, attracting the best global talent, UK manufacturing resilience and addressing the challenges of scaling.

The BIA moves into a new era this week, amidst news from the US on tariffs for UK pharma, UK political party conferences underway and a change in leadership at GSK. It’s full steam ahead for BIA towards a busy Autumn, ensuring that the life science sector stays at the top of the government’s priority list and that our members are represented and connected.

MoU will explore collaborative opportunities in biomedicine, biotechnology and bioinformatics, with a strong emphasis on AI applications.